DEWB AG Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
808
0 Kommentare
DEWB Investment Holding NOXXON Presents Data from Phase IIa Study with NOX-H94
808 
0 KommentareBusiness news for the stock market
Berlin (pta031/08.04.2014/14:05) - Anti-Hepcidin Spiegelmer® Lexaptepid Pegol Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study
Potential Diagnostic Markers Identified to Predict Response
Berlin, Germany - 8 April 2014 - NOXXON Pharma announced that data from a Phase IIa pilot study in anemic cancer patients treated with lexaptepid pegol (NOX H94) will be presented today at the annual
meeting of the American Association for Cancer Research (AACR) in San Diego, CA.
Lexaptepid pegol is a Spiegelmer® that binds and neutralizes hepcidin, a peptide hormone that negatively regulates serum iron levels. High hepcidin levels, commonly found in patients with cancer or in dialysis patients, lead to iron restriction, also known as functional iron deficiency: a condition in which iron is blocked inside its cellular stores and is thus unavailable for hemoglobin synthesis. This condition, over time, results in anemia of chronic disease.
The objective of this single-arm, open label, multi-center study was to evaluate the efficacy, pharmacokinetics, safety and tolerability of treatment with lexaptepid pegol. Twelve cancer patients with anemia (hemoglobin < 10 g/dL) were treated for four weeks with twice weekly intravenous infusions of lexaptepid pegol. This treatment period was followed by a one month observation period. No treatment with ESAs (erythropoiesis stimulating agents) such as EPO (erythropoietin) or iron products was allowed during the study period.
The results showed significant increases in hemoglobin levels (>1 g/dL) in 5 of 12 (42%) patients in response to lexaptepid pegol monotherapy. Increased hemoglobin was maintained throughout the follow-up period. For reference, the combination of EPO and intravenous iron in a similar population resulted in a response in 65% of patients(1). Lexaptepid pegol responders showed increases of both red cell and reticulocyte hemoglobin and a decrease in soluble transferrin receptor levels. This latter marker is an indicator of increased iron demand, and was identified as one of two promising diagnostic predictors along with reticulocyte hemoglobin content.
Following this positive pilot study, NOXXON plans to initiate soon a new study with lexaptepid pegol in EPO-hyporesponsive dialysis patients.
The title and contributors to the poster presentation at AACR are as follows:
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM, Hall A-E, Abstract 3847, Poster 8 The anti-hepcidin Spiegelmer® lexaptepid pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study Pencho Georgiev, Mihaela Lazaroiu, Luminita Ocroteala, Janet Grudeva-Popova, Emanuil Gheorghita, Mariana Vasilica, Sanda M Popescu, Andrei Cucuianu, Luciana Summo, Frank Schwoebel, Kai Riecke, Heinz Ludwig Members of NOXXON's drug development team will be at the AACR conference to explain the mode of action and clinical potential of this innovative drug candidate.
Lexaptepid pegol is a Spiegelmer® that binds and neutralizes hepcidin, a peptide hormone that negatively regulates serum iron levels. High hepcidin levels, commonly found in patients with cancer or in dialysis patients, lead to iron restriction, also known as functional iron deficiency: a condition in which iron is blocked inside its cellular stores and is thus unavailable for hemoglobin synthesis. This condition, over time, results in anemia of chronic disease.
The objective of this single-arm, open label, multi-center study was to evaluate the efficacy, pharmacokinetics, safety and tolerability of treatment with lexaptepid pegol. Twelve cancer patients with anemia (hemoglobin < 10 g/dL) were treated for four weeks with twice weekly intravenous infusions of lexaptepid pegol. This treatment period was followed by a one month observation period. No treatment with ESAs (erythropoiesis stimulating agents) such as EPO (erythropoietin) or iron products was allowed during the study period.
The results showed significant increases in hemoglobin levels (>1 g/dL) in 5 of 12 (42%) patients in response to lexaptepid pegol monotherapy. Increased hemoglobin was maintained throughout the follow-up period. For reference, the combination of EPO and intravenous iron in a similar population resulted in a response in 65% of patients(1). Lexaptepid pegol responders showed increases of both red cell and reticulocyte hemoglobin and a decrease in soluble transferrin receptor levels. This latter marker is an indicator of increased iron demand, and was identified as one of two promising diagnostic predictors along with reticulocyte hemoglobin content.
Following this positive pilot study, NOXXON plans to initiate soon a new study with lexaptepid pegol in EPO-hyporesponsive dialysis patients.
The title and contributors to the poster presentation at AACR are as follows:
Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM, Hall A-E, Abstract 3847, Poster 8 The anti-hepcidin Spiegelmer® lexaptepid pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study Pencho Georgiev, Mihaela Lazaroiu, Luminita Ocroteala, Janet Grudeva-Popova, Emanuil Gheorghita, Mariana Vasilica, Sanda M Popescu, Andrei Cucuianu, Luciana Summo, Frank Schwoebel, Kai Riecke, Heinz Ludwig Members of NOXXON's drug development team will be at the AACR conference to explain the mode of action and clinical potential of this innovative drug candidate.
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Verfasst von Pressetext (Adhoc)
URL kopieren
Per E-Mail teilen
Artikel drucken
Artikel zu den Werten
Auch bei Lesern beliebt
